Red bone marrow is mainly distributed in pelvis, lumbar, and thoracic vertebrae and has highly hematopoietic activity. Bone marrow can be divided into red bone marrow and yellow bone marrow. The standard treatment for locally advanced cervical cancer (LACC) (FIGO stage IB2-IVA) is concurrent chemoradiotherapy (CRT), which can improve the overall survival and local control rate and make the 3-year disease-free survival rate reaching 40%–75% ( 2, 3). A p-value40% BM ACT% was 0.148 times less than in 30%–40% BM ACT% (p = 0.037, OR = 0.148, 95% CI = 0.025–0.892).Ĭonclusion: Baseline 18FDG PET/CT BM ACT% could help predict the severity of HT during CRT for LACC.Ĭervical cancer is the fourth most common cancer among women in the world ( 1). The correlations among age, body mass index, FIGO stage, differentiation, maximum diameter of primary lesion, parametrial invasion, lymph node metastasis, pelvic active bone marrow volume (BM ACT), BM ACT volume percentage (BM ACT%), maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and HT were analyzed using hypothesis testing and logistic regression.

Methods and materials: Forty-one patients with LACC undergoing concurrent CRT were retrospectively analyzed. Purpose: The aim of this study is to evaluate the value of 18FDG PET/CT metabolic parameters in predicting hematological toxicity (HT) during chemoradiotherapy (CRT) for locally advanced cervical cancer (LACC). 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China.1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China.

Tianyu Meng 1, Xiangxi Meng 1*, Xiaoxia Xu 1, Xiaofan Li 2, Zhi Yang 1* and Nan Li 1*

Braveland blood and bones